Characteristics,Management,and Outcomes of Latent Tuberculosis Reactivation Following the Use of Biologics for Psoriasis: A Systematic Review

Abstract

Keywords

Mycobacterium tuberculosis TB reactivation biologics psoriasis TNF-alpha inhibitors IL-17 inhibitors IL-23 inhibitors IL-12/23 inhibitors

Get full access to this article

View all access options for this article.

References

Lopez-Trujillo

Pesqué

Sanchez

, et al. Active tuberculosis in a cohort of patients with psoriasis on biologic therapy: learnings from real-life medical practice. J Eur Acad Dermatol Venereol. 2022;36(9):e689-e691. doi:10.1111/jdv.18131

Yuan

Lin

, et al. Safety of biologics for psoriatic patients with latent tuberculosis. Clin Cosmet Investig Dermatol. 2023;16:2333-2336. doi:10.2147/ccid.s426253

Lin

Plessner

Voitenok

Flynn

. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc. 2007;12(1):22-25. doi:10.1038/sj.jidsymp.5650027

Philippot

Ogishi

Bohlen

, et al. Human IL-23 is essential for IFN-γ–dependent immunity to mycobacteria. Sci Immunol. 2023;8(80):eabq5204. doi:10.1126/sciimmunol.abq5204

Torrado

Cooper

. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev. 2010;21(6):455-462. doi:10.1016/j.cytogfr.2010.10.004

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.01 MB

0.11 MB

0.01 MB

0.03 MB

0.00 MB